1. Pink Sheet

Inside The COVID-19 Bill: Breaking Down The Pharma Policy Provisions

 
• By Derrick Gingery, Cathy Kelly, and Sarah Karlin-Smith

What's in – and what fell out of – the massive US stimulus package.

Overall, the massive legislation coronavirus that passed the Senate and is headed to a House vote and then President Trump's desk is a mixed blessing for the pharmaceutical industry, containing an important proviso related to drug pricing, but missing several potentially significant policy changes that were included in draft legislation at the beginning of the process. Below is a look at some of the major provisions in various versions of the bill; manufacturing elements of the legislation will be addressed in a subsequent table.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legislation

More from Pink Sheet

EMA To Consider Approvals For Eight Orphans, Including Vertex’s CF Drug Alyftrek

 
• By Francesca Bruce

The European Medicines Agency is this week expected issue opinions on whether the European Commission should grant EU marketing authorization for 19 new products.

Kiji CEO On EU HTA Regulation, Hospital Exemption And The Future Of ATMPs

 
• By Eliza Slawther

Miguel Forte, CEO of Kiji Therapeutics, tells the Pink Sheet why he is confident in the future of gene therapies, despite the global “turmoil” that is impacting investment in the industry and changes to the EU and US regulatory landscapes.

Companies Advised To Assess Potential Impacts Of Landmark Global Pandemic Treaty

 
• By Neena Brizmohun

Mechanisms in the draft treaty that the more than 190 member states of the World Health Organization have finally agreed to are expected to “materially affect companies,” particularly those that develop, manufacture or distribute pandemic-related health care products.